Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist drug used for the treatment of type 2 diabetes and obesity. It was developed by the Danish pharmaceutical company Novo Nordisk and approved by the FDA in 2017 under the brand name Semaglutide as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
What is Semaglutide?
Semaglutide is a GLP-1...
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian